Pegasys Newswire

Pegasys Newswire

Comprehensive Real-Time News Feed for Pegasys.

Results 1 - 18 of 18 in Pegasys

  1. Roche Profit Dented by Strong Swiss FrancRead the original story w/Photo

    Wednesday Jan 27 | Wall Street Journal

    Swiss drugmaker Roche Holding AG on Thursday reported 5% fall in full-year net income as the strong Swiss franc countered gains from the company's diagnostics business and its all-important breast cancer treatments.

    Comment?

  2. Roche Holding Ltd. (RHHBY) Downgraded by Zacks Investment Research to "Sell"Read the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    ... with drugs like Actemra, Xolair, MabThera and Esbriet. However, generic competition for Xeloda, Zelboraf and Pegasys continues to hamper sales. Lucentis is also facing strong competition in the DME and wet-AMD space. Additionally, currency ...

    Comment?

  3. Lab Automation Market - Global Industry Analysis, Size, Share,...Read the original story w/Photo

    Nov 17, 2015 | SBWire

    Laboratory automation is the usage of technology and equipment in laboratories to raise experimental data quality, reduce lab process cycleand in diagnostics. Laboratory automation encompassesprocess, devices, technology and software thatsupport automated workflow process in the laboratories and thus decrease manual steps and faults.

    Comment?

  4. REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infectionRead the original story w/Photo

    Nov 16, 2015 | Aidsmap

    ... 2139-Ca at a reduced dose of 250mg once weekly for another 15 weeks plus 180 mcg/week pegylated interferon alfa-2a ( Pegasys ) continued for 48 weeks. All participants experienced declines in serum HBsAg during REP 2139-Ca monotherapy, though ...

    Comment?

  5. Roche Holding's (RHHBF) CEO Severin Schwan on Q3 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Oct 22, 2015 | Seeking Alpha

    ... later in the lifecycle of facing competition. I'll touch on all of these in the coming slides with the exception of Pegasys where we're really now seeing the complete launch of the interferon-free therapies and Xeloda and Valcyte, as you know, both ...

    Comment?

  6. Roche sees strong growth from breast cancer drugsRead the original story w/Photo

    Oct 22, 2015 | MarketWatch

    Roche Holding AG expects strong growth from its recent breast cancer drugs Perjeta and Kadcyla well into 2017, the company's head of pharmaceuticals said. Perjeta and Kadcyla increased sales by 66% and 57% respectively in the first nine months of 2015, Roche said Thursday as the Basel company announced a 2% increase in sales during the period.

    Comment?

  7. Roche lifts outlook on strong cancer drug salesRead the original story w/Photo

    Oct 22, 2015 | MarketWatch

    Roche Holding AG on Thursday raised its annual outlook as strong sales of its cancer and immunology treatments helped the Swiss pharmaceuticals giant overcome the highly valued Swiss franc. Basel-based Roche said sales for the three months to Sept.

    Comment?

  8. Roche posts rise in sales, overcoming strong francRead the original story w/Photo

    Oct 21, 2015 | MarketWatch

    Roche Holding AG on Thursday reported a slight increase in third-quarter sales as strong sales of its oncology and immunology treatments helped the Swiss pharmaceuticals giant overcome the highly-valued Swiss franc. Basel-based Roche said sales for the three months ended Sept.

    Comment?

  9. Roche Holding Given Average Recommendation of "Buy" by AnalystsRead the original story

    Oct 14, 2015 | AmericanBankingNews.com

    Roche Holding has received a consensus rating of "Buy" from the ten analysts that are covering the stock, Market Beat Ratings reports . Three analysts have rated the stock with a hold rating and seven have issued a buy rating on the company.

    Comment?

  10. Indian Drugmakers Engineer Hepatitis C Pills Impossible in WestRead the original story w/Photo

    Oct 9, 2015 | Bloomberg

    ... Valcyte. In 2012, an Indian patent appeals board revoked patent protection for Roche's hepatitis C injection Pegasys. The patent office didn't answer calls seeking comment. If the patent challenges on the Gilead and Bristol-Myers drugs fail, Indian ...

    Comment?

  11. Regulatory backlog in emerging nations adding years to drug approvals - RocheRead the original story

    Sep 8, 2015 | Reuters

    A regulatory backlog in developing countries including China has created wait times for drugs awaiting approval of up to seven years, Roche Holding AG Chief Executive Severin Schwan said on Tuesday. "Unfortunately, time lines are getting longer and longer in countries like China," Schwan said at an oncology event at the Swiss company's headquarters in Basel.

    Comment?

  12. Roche gets FDA breakthrough designation for ACE910Read the original story w/Photo

    Sep 4, 2015 | MarketWatch

    Roche Holding AG said Friday the U.S. Food and Drug Administration has given breakthrough therapy designation to its ACE910 prophylactic remedy for treating haemophilia A, potentially speeding up its availability for patients with the disease. Basel-based Roche said the FDA based its decision on clinical research that showed weekly subcutaneous injections with ACE910 produced promising results in treating patients 12 years and older with haemophilia A with factor VII inhibitors.

    Comment?

  13. Roche buys U.S.-based Kapa BiosystemsRead the original story w/Photo

    Aug 19, 2015 | MarketWatch

    Roche Holding AG Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company. Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum.

    Comment?

  14. Roche buys privately-held GeneWEAVE BioSciencesRead the original story w/Photo

    Aug 13, 2015 | MarketWatch

    Roche Holding AG Thursday said it has agreed to buy a U.S. microbiology diagnostic company in a deal which could rise up to $425 million - the latest acquisition in the Swiss pharmaceuticals giant's deeper push into diagnostics. Basel-based Roche said it was buying privately-held GeneWEAVE BioSciences Inc., based in Los Gatos, California, for an initial $190 million and would pay up to $235 million extra depending on the development of products.

    Comment?

  15. Roche gets EU approval for cancer drug PerjetaRead the original story w/Photo

    Jul 31, 2015 | MarketWatch

    European regulators approved Roche Holding AG's Perjeta remedy for the pre-surgery treatment of adult patients with breast cancer. Basel-based Roche Friday said the European Commission approved the use of its cancer drug Perjeta, in combination with Herceptin and chemotherapy, for early stage treatment of a type of aggressive breast cancer which carries a high risk of recurrence.

    Comment?

  16. Roche holds hope for second test of Alzheimer's drugRead the original story w/Photo

    Jun 9, 2015 | Star Tribune

    Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?

  17. Roche Holding Cut to Sell at ZacksRead the original story

    Jun 9, 2015 | AmericanBankingNews.com

    ... solutions for early detection and treatment of diseases. However, generic competition for Xeloda, Zelboraf and Pegasys will continue to hamper sales. Lucentis is also expected to face strong competition in the DME and wet AMD space. Generics are ...

    Comment?

  18. Roche takes another shot at Alzheimer's drugRead the original story w/Photo

    Jun 9, 2015 | Salt Lake Tribune

    Geneva a Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise in slowing the memory-robbing ailment. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?